Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Monte Rosa Therapeutics and Exicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
| Exicure | N/A | -237.91% | -61.98% |
Risk & Volatility
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Monte Rosa Therapeutics and Exicure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
Monte Rosa Therapeutics currently has a consensus price target of $27.62, suggesting a potential upside of 168.20%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Monte Rosa Therapeutics is more favorable than Exicure.
Earnings & Valuation
This table compares Monte Rosa Therapeutics and Exicure”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $123.67 million | 7.11 | -$38.63 million | ($1.76) | -5.85 |
| Exicure | $500,000.00 | 13.76 | -$4.95 million | ($1.32) | -0.80 |
Exicure has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Exicure on 8 of the 15 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
